Cargando…

Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?

Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has emerged into a global health and economic menace. Amidst the COVID-19 turmoil, recent failures/uncertain outcomes in clinical trials involving the anti-malarial (hydro...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunjegaonkar, Shivshankar Malkarjun, Shanmugarajan, Thukani Sathanantham, Arunsundar, Mohanasundaram, Arjun, Uppuluri Varuna Naga Venkata, Devi, Kadirrel, Wankhede, Sagar Baliram, Ravichandiran, Velayutham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603945/
https://www.ncbi.nlm.nih.gov/pubmed/34238584
http://dx.doi.org/10.1016/j.therap.2020.10.004
_version_ 1783604028116041728
author Gunjegaonkar, Shivshankar Malkarjun
Shanmugarajan, Thukani Sathanantham
Arunsundar, Mohanasundaram
Arjun, Uppuluri Varuna Naga Venkata
Devi, Kadirrel
Wankhede, Sagar Baliram
Ravichandiran, Velayutham
author_facet Gunjegaonkar, Shivshankar Malkarjun
Shanmugarajan, Thukani Sathanantham
Arunsundar, Mohanasundaram
Arjun, Uppuluri Varuna Naga Venkata
Devi, Kadirrel
Wankhede, Sagar Baliram
Ravichandiran, Velayutham
author_sort Gunjegaonkar, Shivshankar Malkarjun
collection PubMed
description Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has emerged into a global health and economic menace. Amidst the COVID-19 turmoil, recent failures/uncertain outcomes in clinical trials involving the anti-malarial (hydroxychloroquine), anti-viral (remdesivir) or the combination of anti-malarial/antibiotic (hydroxychloroquine/azithromycin) regimens have predisposed the physicians to distrust these “highly-touted” drugs for COVID-19. In this milieu, immunotherapy might be a credible modality to target or modify specific/non-specific immune responses that interfere with the survival of intracellular pathogens. This scientific review throws light on the epidemiology of COVID-19, its pathogenesis and the current clinical scenario of immunotherapeutics including convalescent plasma (CP), type-1 interferons (IFN–I) and human monoclonal antibodies (mAbs) to combat COVID-19. The treatment outcomes underscore that immunotherapy might be a reliable tool to assuage COVID-19-associated immunopathology. However, specific patient pool studies are warranted to ascertain the precise (re)purposing of immunotherapeutics for COVID-19.
format Online
Article
Text
id pubmed-7603945
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-76039452020-11-02 Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet? Gunjegaonkar, Shivshankar Malkarjun Shanmugarajan, Thukani Sathanantham Arunsundar, Mohanasundaram Arjun, Uppuluri Varuna Naga Venkata Devi, Kadirrel Wankhede, Sagar Baliram Ravichandiran, Velayutham Therapie Therapeutics Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has emerged into a global health and economic menace. Amidst the COVID-19 turmoil, recent failures/uncertain outcomes in clinical trials involving the anti-malarial (hydroxychloroquine), anti-viral (remdesivir) or the combination of anti-malarial/antibiotic (hydroxychloroquine/azithromycin) regimens have predisposed the physicians to distrust these “highly-touted” drugs for COVID-19. In this milieu, immunotherapy might be a credible modality to target or modify specific/non-specific immune responses that interfere with the survival of intracellular pathogens. This scientific review throws light on the epidemiology of COVID-19, its pathogenesis and the current clinical scenario of immunotherapeutics including convalescent plasma (CP), type-1 interferons (IFN–I) and human monoclonal antibodies (mAbs) to combat COVID-19. The treatment outcomes underscore that immunotherapy might be a reliable tool to assuage COVID-19-associated immunopathology. However, specific patient pool studies are warranted to ascertain the precise (re)purposing of immunotherapeutics for COVID-19. Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2021 2020-11-01 /pmc/articles/PMC7603945/ /pubmed/34238584 http://dx.doi.org/10.1016/j.therap.2020.10.004 Text en © 2020 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Therapeutics
Gunjegaonkar, Shivshankar Malkarjun
Shanmugarajan, Thukani Sathanantham
Arunsundar, Mohanasundaram
Arjun, Uppuluri Varuna Naga Venkata
Devi, Kadirrel
Wankhede, Sagar Baliram
Ravichandiran, Velayutham
Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?
title Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?
title_full Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?
title_fullStr Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?
title_full_unstemmed Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?
title_short Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?
title_sort harnessing immunotherapy to combat covid-19: a modern snake oil or silver bullet?
topic Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603945/
https://www.ncbi.nlm.nih.gov/pubmed/34238584
http://dx.doi.org/10.1016/j.therap.2020.10.004
work_keys_str_mv AT gunjegaonkarshivshankarmalkarjun harnessingimmunotherapytocombatcovid19amodernsnakeoilorsilverbullet
AT shanmugarajanthukanisathanantham harnessingimmunotherapytocombatcovid19amodernsnakeoilorsilverbullet
AT arunsundarmohanasundaram harnessingimmunotherapytocombatcovid19amodernsnakeoilorsilverbullet
AT arjunuppulurivarunanagavenkata harnessingimmunotherapytocombatcovid19amodernsnakeoilorsilverbullet
AT devikadirrel harnessingimmunotherapytocombatcovid19amodernsnakeoilorsilverbullet
AT wankhedesagarbaliram harnessingimmunotherapytocombatcovid19amodernsnakeoilorsilverbullet
AT ravichandiranvelayutham harnessingimmunotherapytocombatcovid19amodernsnakeoilorsilverbullet